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DOI 10.1016/j.ccr.2010.03.008SUMMARYThe biologic and clinical significance of KIT overexpression that associates with KIT gain-of-function muta-
tions occurring in subsets of acute myeloid leukemia (AML) (i.e., core binding factor AML) is unknown. Here,
we show thatKITmutations lead toMYC-dependentmiR-29b repression and increased levels of themiR-29b
target Sp1 in KIT-driven leukemia. Sp1 enhances its own expression by participating in a NFkB/HDAC
complex that further repressesmiR-29b transcription. Upregulated Sp1 then binds NFkB and transactivates
KIT. Therefore, activated KIT ultimately induces its own transcription. Our results provide evidence that the
mechanisms of Sp1/NFkB/HDAC/miR-29b-dependent KIT overexpression contribute to leukemia growth
and can be successfully targeted by pharmacological disruption of the Sp1/NFkB/HDAC complex or
synthetic miR-29b treatment in KIT-driven AML.INTRODUCTION
The KIT gene encodes a 145 kDa transmembrane protein that is
a member of the type III receptor tyrosine kinase (RTK) family
(Yarden et al., 1987), regulates cell survival, proliferation or differ-
entiation (Schlessinger, 2000), and participates in normal mech-
anisms of hematopoiesis, melanogenesis, and gametogenesis.
KIT protein expression is modulated by a variety of mechanisms
including microRNAs (miRNAs) (Felli et al., 2005) and/or proteo-
lytic degradation (Masson et al., 2006) and is subjected to cova-
lent posttranslational modifications, which influence its tyrosine
kinase activity through interaction with a variety of factorsSignificance
KIT encodes a tyrosine kinase receptor that activates down
Overexpression of mutated or wild-type KIT alleles occurs in s
supporting a critical role of high levels of the KIT protein in leuk
RNA network, Sp1/NFkB/HDAC/miR-29b, that results in KIT ov
network is targetable by proteasome, NFkB, Sp1, or HDAC in
provide antileukemic activity by decreasing KIT expression th
sent promising therapeutic approaches to disrupt KIT express
AML.including KIT ligand (also known as stem cell factor), tyrosine
phosphatases (Kozlowski et al., 1998), protein kinase C, and
calcium ionophores (Miyazawa et al., 1994; Yee et al., 1993).
KIT is overexpressed and/or mutated in several human
neoplasms, including gastrointestinal stromal tumors (GISTs),
germ cell tumors, and hematologic malignancies (Ikeda et al.,
1991). In acute myeloid leukemia (AML), while KIT expression
is detectable in the majority of the cases (Ikeda et al., 1991),
gain-of-function mutations resulting in constitutive tyrosine
kinase activity appear to be restricted to core binding factor
(CBF) disease [(8;21) or inv(16) or the respective molecular
equivalent RUNX1/RUNX1T1- or CBFB/MYH11-positive AML],stream pathways leading to cell proliferation and survival.
pecific subsets of AML and predicts poor outcome, thereby
emogenesis. Here we report deregulation of a protein-micro-
erexpression in KIT-driven leukemia. We also show that this
hibitors or ectopic miR-29b expression. These compounds
rough miR-29b-dependent Sp1 downregulation, and repre-
ion and efficiently override aberrant KIT activity in KIT-driven
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Figure 1. KIT Expression in AML Patients and Cell Lines
(A) KIT expression in bone marrow from Cancer and Leukemia Group B AML
patients.
(B) KIT protein expression in various AML or mastocytosis (HMC-1) cell lines.
+ or indicates presence or absence of KITmut or KITwt alleles. Data are repre-
sentative of three independent experiments. (See also Figure S1).
Cancer Cell
MicroRNA Network Regulating KIT Expression in AMLin which these mutations associate with unfavorable outcome
(Paschka et al., 2006).
Tyrosine kinase (TK) inhibitors (e.g., imatinib, dasatinib or
PKC412 [midostaurin]) have been shown to suppress aberrant
activity of KIT mutants and delay tumor growth (Heinrich et al.,
2002; Growney et al., 2005). However, clinical response to these
compounds depends mostly on the nature of KIT mutations
(Heinrich et al., 2002). For example, KIT mutations in codon
822 are sensitive to imatinib, whereas mutations in codon 816
are not and can be targeted successfully with midostaurin or
dasatinib. Therefore, to take fully clinical advantage of the thera-
peutic approach with inhibitors, the type of KIT mutation needs
to be identified at the time of initial diagnosis. Even if this strategy
is adopted, however, the sensitivity of a distinct KIT mutation to
an optimally chosen TK inhibitor is likely to decrease over time
due to acquisition of secondary KIT mutations (Gajiwala et al.,
2009) that mediate resistance (Heinrich et al., 2008). These
observations justify investigation of novel strategies to effectively
target all KIT mutations and improve the likelihood of inducing
durable clinical responses in KIT-driven malignancies. Flavopir-
idol and KIT siRNA have been shown to downmodulate KIT
transcription and induce apoptosis in GIST cells (Sambol et al.,
2006). Therefore, direct targeting of KIT expression may repre-
sent a valuable approach to overcome aberrant KIT enzymatic
activity and circumvent the drawbacks of TK inhibitor therapies
in AML. This strategy, however, can be effectively developed
and implemented only if the regulatory mechanisms controlling
the expression of both the wild-type and mutated KIT alleles in
myeloid cells are elucidated.
The overarching goal of the present study is to characterize
the molecular pathways that control aberrant expression of
both wild-type and mutated KIT alleles in AML and devise
molecular targeting strategies to downregulate KIT and, in turn,
attain significant and durable antileukemic activity in KIT-driven
leukemia.
RESULTS
KIT Overexpression in AML
Aberrant KIT protein activity plays a pivotal role in human malig-
nancies. Although KIT expression is relatively common in blasts
from all AML subtypes, activating KIT mutations appear to be
restricted to CBF AML, where they predict poor outcome
(Paschka et al., 2006). In CBF AML, the KIT gene also appears
to be overexpressed. In a cohort of Cancer and Leukemia Group
B (CALGB) patients, we showed that RUNX1/RUNXT1-positive
patients with KIT mutation (KITmut) or wild-type (KITwt) have
higher KIT levels compared with patients with cytogenetically
normal (CN) AML (Figure 1A). Interestingly, KIT overexpression
adversely impacts outcome, and RUNX1/RUNXT1-positive
patients with higher KIT levels had a significantly shorter survival
(p = 0.04; see Figure S1A available online). Among AML cell lines,
higher levels of KIT expression are also found in CBF AML cell
lines, i.e., RUNX1/RUNXT1-positive and KITmut Kasumi-1 and
SKNO-1 and CBFB/MYH11-positive and KITwt ME-1, when
compared with non-CBF cell lines (Figure 1B and Figure S1B).
Thus, we hypothesized that in distinct molecular subsets of
AML like CBF AML, the KIT protein is aberrantly activated and
upregulated. We also hypothesized that KIT overexpression334 Cancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc.itself contributes to leukemogenesis and therefore should be
therapeutically targeted in KIT-driven AML. In order to prove
these hypotheses, however, the mechanisms that govern KIT
expression and its leukemogenic role in KIT-driven leukemia
need to be fully elucidated.
Sp1/NFkB Modulates KIT Expression in AML
To start unraveling the regulatory mechanisms of KIT expression
in AML, we examined the KIT promoter region for transcription
factor binding sites, and identified binding sites for both Sp1
and NFkB in a 1kb region spanning the human KIT gene
promoter. Because we and others have recently shown that
transactivation of certain oncogenes (e.g., DNMT1) involved in
leukemogenesis requires physical interaction of the transcription
factors Sp1 and NFkB (Liu et al., 2008; Hirano et al., 1998), we
reasoned that the Sp1/NFkB complex is likely to be also involved
in modulation of KIT expression in KIT-driven leukemia cells.
To support this hypothesis, we performed electrophoretic
mobility-shift assays (EMSA) using probes spanning the Sp1/
NFkB binding sites (XN2 probe) on the KIT promoter or
consensus binding elements for Sp1 (Sp1C) or NFkB (NFkBC)
on nuclear extracts from Kasumi-1 cells. These cells were
selected because they harbor mutated and overexpressed KIT
(Figure 1B). The DNA-protein complexes attained with the XN2
probe comigrated with those attained with the Sp1C and NFkBC
probes, supporting enrichment of both Sp1 and NFkB on the
KIT promoter (Figure 2A, lanes 2, 5, and 8). These data were
Cancer Cell
MicroRNA Network Regulating KIT Expression in AMLconfirmed by chromatin immunoprecipitation (ChIP) showing
Sp1 and NFkB enrichment on the KIT promoter (Figure 2B).
Higher levels of Sp1 enrichment on the KIT promoter were
observed in Kasumi-1 cells that harbor overexpressed KITmut
compared with AML lines (MV4-11 and THP-1) carrying lower
levels of KITwt (Figure 2B).
To further assess the biological role of Sp1 and NFkB on KIT
expression, we applied loss- and gain-of-function approaches
in Kasumi-1 cells. First we showed that ectopic expression
(Figure 2C, left panel) or siRNA knockout (Figure 2C, right panel),
respectively, reduced and increased Sp1 and NFkB(p65) enrich-
ment on the KIT promoter, and resulted, respectively, in KIT
downregulation or upregulation in Kasumi-1 cells (Figure 2D).
The role of Sp1 in KIT gene transcription was further elucidated
by treating Kasumi-1 cells or AML patient primary blasts with
mithramycin A, a previously reported Sp1 inhibitor (Ray et al.,
1989). Mithramycin A exposure led to decrease in KIT RNA tran-
scription and protein expression (Figure 2E) in both Kasumi-1
and patient primary cells and time- and dose-dependent inhibi-
tion of Kasumi-1 cell proliferation (Figure S2). With regard to
NFkB function, exposure to the NFkB inhibitor bay11-7082
decreased Sp1 and KIT expression (Figure 2F).
Sp1 expression and functions are, in part, regulated via the 26S
proteasome, a common pathway controlling the degradation of
a plethora of other survival factors (Karin et al., 2004; Pagano
et al., 1995). Activation of NFkB is also controlled by the 26S pro-
teasome (Bargou et al., 1997; Mori et al., 2000). We have also
previously reported that the26Sproteasome inhibitorbortezomib
interferes with Sp1/NFkB activity (Liu et al., 2008). To further
establish the regulatory role of the Sp1/NFkB complex in
KIT expression, we treated Kasumi-1 cells with bortezomib. The
pharmacologic activity of bortezomib was then demonstrated
by accumulation of polyubiquitinated proteins indicating ade-
quate proteasome inhibition, concurrent increase in expression
of the Noxa and p21 genes, and miR-29b occurring prior to any
evidence of obvious cytotoxicity (Figures S3A–S3D and S3G).
In agreement with recent reports (Hideshima et al., 2009), we
also observed that bortezomib resulted in NFkBp65 and IKBa
phosphorylation (Figure S3E), thereby suggesting possible
activation of the NFkB canonical pathway in Kasumi-1 cells.
Concurrent with these changes, however, we also evidenced
increase in Sp1 ubiquitination, more diffused Sp1 nucleus/cyto-
plasm localization, and most importantly disruption of the Sp1
and NFkB physical interaction (Figures S3E and S3F). The latter
was likely to abrogate Sp1/NFkB gene transactivating activity
thereby leading to bortezomib-induced dose- and time-depen-
dent reduction in KIT expression (Figures 3A and 3B; see also
Figure S3H) as observed in Kasumi-1 cells and confirmed
in primary blasts from three RUNX1/RUNX1T1-positive and
KITmut AML patients diagnosed at our institution (Figure 3C).
Moreover, we found that bortezomib not only induced KIT
downregulation, but also KIT dephosphorylation (Figure 3B) and
inhibition of KIT-dependent downstream signaling effectors
(Figure 3D). Decreased protein expression and phosphorylation
of tyrosine (tyr) or serine (ser) residues of STAT1 (tyr701), STAT3
(tyr705), AKT (ser473), and ERK (tyr204) were observed in
Kasumi-1 cells upon exposure to bortezomib (Figure 3E). Hence,
these results support a critical role of both Sp1 and NFkB on KIT
expression and in turn on KIT aberrant kinase activity in leukemia.MiR-29b Modulates KIT Expression by Targeting Sp1
through an Autoregulatory Loop
Sp1 is a bona fide target of miR-29b (Garzon et al., 2009). The
clinical relevance of this finding was supported here by the nega-
tive linear correlation between Sp1 and miR-29b expression
levels in RUNX1/RUNX1T1–positive AML patients (Spearman’s
correlation coefficient 0.6; p = 0.016; Figure S4A). Consistent
with these results, these patients have high Sp1/miR-29b ratio
(Figure 4A).
Given that miRNAs are frequently involved in feedback loops
where they target the same factors that regulate their expression
(Tsang et al., 2007) and Sp1 participates in KIT transactivation,
we then hypothesized a microcircuitry mechanism where Sp1
represses miR-29b transcription and this in turn increases Sp1
at levels sufficient to participate with NFkB in KIT transcriptional
upregulation. Consistent with our hypothesis, forced miR-29b
expression in Kasumi-1 cells led to KIT protein downregulation,
while decreased miR-29b expression by antagomiR-29b led
to upregulation of KIT (Figure 4B). Furthermore, exposure of
Kasumi-1 cells to mithramycin A, bay11-7082 or bortezomib,
that interfere respectively with Sp1, NFkB or Sp1/NFkB activi-
ties, resulted not only in KIT downregulation (Figures 2E and F;
Figure 3A and B), but also in increased miR-29b expression
(Figure 4C) and in turn downregulation of the miR-29b target
Sp1 (Figure 4D). Collectively these data suggest that miR-29b
participates in modulating KIT level by regulating expression of
Sp1 and its participation in transcriptional regulation complexes
with NFkB. The clinical relevance of the miR-29b in KIT-driven
AML was supported by the observation that RUNX1/RUNX1T1–
positive patients, who showed worse survival when expressing
higher KIT levels, tended also to have worse outcome when
expressing lower miR-29 levels (Figure S4B).
Next we focused on dissecting the mechanisms of miR-29b
transcriptional regulation. We identified three Sp1 and one
NFkB binding sites within a 1 kb span of DNA upstream from
the50 endof theprimary transcript ofmiR-29bonhumanchromo-
some 7 (using the software package available at www.gene-
regulation.com) (Figure 5A). To determine whether a functional
interaction occurred between Sp1/NFkB and the miR-29b
upstream regulatory sequence, we initially performed EMSA
assays using probes (see Supplemental Information) spanning
the 125/75 miR-29b sequence in K562 cells. These cells
were selected because they have high levels of Sp1 while
expressing low levels of endogenous miR-29b (Garzon et al.,
2009). As shown in Figure 5B (left panel, lane 2), the 29BNFkBSp1
probe containing both Sp1 and NFkB binding sites yielded
two major complexes (indicated as C1 and C2), suggesting
that both Sp1 and NFkB interact with elements of the miR-
29b enhancer region. The specificity of the protein-DNA binding
complexes was demonstrated by their abrogation of binding
in the presence of 100-fold excess of unlabeled probes
(29BNFkBSp1, Sp1C, or NFkBC containing both or single Sp1/
NFkB binding site) (Figure 5B, left panel, lanes 3, 4, and 5),
whereas the same-fold excess of an irrelevant oligonucleotide
(TFIIAC) containing the TFIIA binding site failed to change the
profile of these complexes (Figure 5B, left panel, lane 6). Interest-
ingly, the unlabeled Sp1C probe preferentially decreased the C2
complex,whereas the unlabeledNFkBCprobedecreased theC1
complex and eliminated the C2 complex. Similarly, incubation ofCancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc. 335
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Figure 3. Proteasome Inhibition byBortezo-
mib Impairs KIT Expression and Its Down-
stream Signaling Pathway
(A and B) Dose-dependent (left) and time-depen-
dent (right) reduction of KIT RNA and protein
expression and KIT protein phosphorylation in
tyrosine (tyr) 719 residue in Kasumi-1 cells incu-
bated with bortezomib (mean ± SEM).
(C) Inhibitory effect of bortezomib on KIT mRNA
expression was evaluated using qRT-PCR in AML
blasts from three patients with mutated KITmut
t(8;21) AML treated with 60 nM bortezomib for
24 hr (mean and standard deviation [± SD]).
(D and E) Immunoblotting analysis demonstrated
the downregulation of KIT downstream effectors
such as STAT1 (D), STAT3, AKT, and ERK (E) in
Kasumi-1 cells treated with bortezomib. p, phos-
phorylated. Data are representative of three inde-
pendent experiments. (See also Figure S3).
Cancer Cell
MicroRNA Network Regulating KIT Expression in AMLextracts with Sp1 antibody decreased the C1 complex and
eliminated the C2 complex, whereas antibody to NFkBp65
decreased the intensity of both complexes (Figure 5B, right
panel). These data suggest that the C1 and C2 complexes con-
tainedbothSp1andNFkBp65, probablywith different stoichiom-
etry; C1 is likely to contain less Sp1. Similar results were attained
in Kasumi-1 cells (data not shown).
Next, we used gain- and loss-of-function assays to show that
forced expression of Sp1 or NFkB(p65) reduced miR-29b inFigure 2. The Regulatory Role of Sp1/NFkB in KIT Expression
(A) Sp1/NFkB complex is present on KIT promoter. EMSA was performed with nuclear extracts from Kasumi-
oligonucleotides containing Sp1/NFkB binding elements on the KIT promoter region from nucleotides102/
NFkB consensus binding sites (NFkBC). Lanes 1, 4, and 7, free 32P-labeled probes; lanes 2, 5, and 8, contr
treated cells.
(B) Chromatin immunoprecipitation (ChIP) assays to demonstrate Sp1/NFkB on KIT gene promoter in KITmut
and standard error of the mean [± SEM]).
(C) ChIP assays to showSp1/NFkBenrichment onKIT promoter in Kasumi-1 cells transfectedwith NFkBor Sp
panel) (mean ± SEM).
(D) Sp1, NFkB, and KIT protein expression in Kasumi-1 cells transfected with corresponding overexpression
(E) Sp1 inhibition bymithramycin A impaired KIT RNA transcription and protein expression in Kasumi-1 cells (le
panel) (mean ± SEM).
(F) NFkB inhibitor bay11-7082 (3 mM) decreased KIT expression in Kasumi-1 cells. Data are representa
Figure S2).
Cancer Cell 17, 333–3MV4-11, an AML cell line with relatively
high endogenousmiR-29b levels (Garzon
et al., 2009), or Kasumi-1 cells (Figure 5C,
left and middle panels). Conversely, Sp1
or NFkB(p65) knockdown by siRNAs
resulted in miR-29b upregulation in K562
cells that have barely detectable levels
of endogenous miR-29b (Garzon et al.,
2009) (Figure 5C, right panel). Consistent
with these results, bortezomib treat-
ment reduced the binding of Sp1/NFkB
complex to miR-29b regulatory elements
(Figure 5D), thereby resulting in miR-29b
re-expression (Figure 4C) and Sp1 reduc-
tion (Figure 4D). Notably, ectopic miR-29b expression disrupted Sp1 binding to themiR-29b enhancer
region (Figure 5E) through abrogation of Sp1 protein and
disruption of Sp1/NFkB DNA binding as confirmed by antibody
supershift (Figure S4C), thereby closing themiR-29b/Sp1 autor-
egulatory loop. Interestingly, ectopic expression of a synthetic
mature miR-29b in K562 cells resulted in an increase of the
endogenousmiR-29b precursor (Figure 5F), thereby further sup-
portingmiR-29b as an active participant in its own transcriptional
regulation.1 cells incubated with 32P-labeled double-stranded
82 (XN2) or Sp1 consensus binding sites (Sp1C) or
ol (untreated) cells; lanes 3, 6, and 9, bortezomib-
Kasumi-1 and KITwt MV4-11 and THP1 cells (mean
1 overexpression vector (left panel) or siRNAs (right
vector (left panel) or siRNA (right panel).
ft andmiddle panels) or patient primary blasts (right
tive of three independent experiments. (See also
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Figure 4. Role ofmiR-29b in KIT Expression
Regulation
(A) Sp1/miR-29b expression ratio (measured by
microarray) in bone marrow samples from Cancer
and Leukemia Group BRUNX1/RUNX1T1-positive
patients with cytogenetically normal AML and
KITmut or KITwt.
(B) Changes in miR-29b expression and KIT
protein levels in Kasumi-1 cells transfected with
miR-29b or antagomiR-29b (A-miR-29b) for 72 hr.
(C) Upregulation of miR-29b in Kasumi-1 cells
treated with bortezomib (60 nM) or bay11-7082
(3 mM) or mithramycin A (150 ng/ml) for 6 hr.
qRT-PCR analysis of miR-29b, normalized by
U44, was performed (mean ± SEM).
(D) Immunoblotting analysis showing reduction of
Sp1 protein in Kasumi-1 cells treatedwith bortezo-
mib or bay11-7082 or mithramycin A. Data are
representative of three independent experiments.
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MicroRNA Network Regulating KIT Expression in AMLHistone Deacetylases Contribute to the Repressor
Activity of Sp1/NFkB onmiR-29b
Having shown that Sp1/NFkB acts as a repressive complex
for miR-29b and as an activating complex for KIT expression,
next we asked whether other factors could participate in
conferring differentiating regulatory functions to this complex.
Although Sp1/NFkB is involved in the regulation of DNA hyper-
methylation (Liu et al., 2008), we observed only few CpG islands
and no obvious DNA methylation of the 50 putative regulatory
region of miR-29b in either AML patient samples or cell lines
with low expression of this miRNA (G.M., unpublished data).
Therefore, we postulated that epigenetic mechanisms causing
chromatin changes other than DNA hypermethylation could be
involved in silencing miR-29b. A number of previous studies
showed that Sp1/NFkB physically interacts with histone deace-
tylases (HDACs) 1 and 3 to repress target gene transcription
(Doetzlhofer et al., 1999). Therefore, in order to test whether
HDAC1 and 3 associate with Sp1/NFkB to repress miR-29b
expression, we incubated 32P-labeled probes designed from
the KIT promoter or miR-29b regulatory regions with recombi-
nant NFkBp50/p65 proteins to form aDNA-protein complex (Fig-
ure 6A, left panel, lanes 2–10). Recombinant Sp1 (Figure 6A, left
panel, lanes 3 or 8), HDAC1 (Figure 6A, left panel, lanes 4 or 9) or
HDAC3 (Figure 6A, left panel, lanes 5 or 10) proteins were then
added. No obvious alterations of the DNA-protein complex
were observed in the KIT promoter indicating that HDAC1338 Cancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc.P
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Figure 5. Regulation of miR-29b Transcription
(A) Schematic diagram showing the location of Sp1 and NFkB binding sites on miR-29b-1 regulatory region on chromosome 7.
(B) EMSA demonstrated that Sp1/NFkB complex was present on the miR-29b regulatory region. Kasumi-1 nuclear extract incubated with 32P-29bNFkBSp1
probe containing NFkB and Sp1 binding sites yielded two DNA-protein complexes C1 and C2 (lane 2). The specificity of DNA binding was demonstrated by
the abolishment or reduction of both complexes with excess (100x) unlabeled 29BNFkBSp1 (lane 3) or Sp1 consensus binding site (Sp1C, lane 4) or NFkB
consensus binding site (NFkBC, lane 5) probes, but not with an irrelevant competitor probe that contains the TFIIA binding site (lane 6). The presence of
NFkB and Sp1 in the DNA-protein complexes was demonstrated by antibody supershift assay (right panel).
(C) Changes in Sp1, NFkB, and miR-29b levels in MV4-11, Kasumi-1 or K562 cell lines transfected with Sp1 or NFkB overexpression vector or siRNA (mean ±
SEM).
(D) EMSA showed that bortezomib treatment diminished the binding of Sp1/NFkB complex to miR-29b regulatory region in Kasumi-1 cells. Control, untreated
cells.
(E and F)miR-29b regulated its own transcription. EctopicmiR-29b expression dissociated Sp1 binding from its own regulatory region by EMSA (E) and synthetic
mature miR-29b enhanced endogenous miR-29b precursor level (F) following 96 hr from initial treatment (mean ± SEM). Data (B–F) are representative of three
independent experiments. (See also Figure S4).
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MicroRNA Network Regulating KIT Expression in AMLMYC expression (Tickenbrock et al., 2008). The latter, in turn,was
shown to downregulatemiR-29b expression (Chang et al., 2008).
Therefore, we postulated that KIT protein activity would driveaberrant KIT gene expression by inducing MYC-dependent
miR-29b downregulation. We validated our hypothesis by show-
ing that treatment with KIT ligand resulted in increase in KIT andCancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc. 339
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Figure 6. HDACs Participate in the
Sp1/NFkB Complex to Inhibit miR-29b
Expression
(A) Using recombinant proteins, EMSA (left panel)
demonstrated the association of HDACs with
Sp1/NFkB on miR-29b regulatory region, which
was confirmed by ChIP (right panel) (mean ±
SEM). 32P-labeled double-stranded oligonucle-
otides containing Sp1 and NFkB consensus
sites from KIT promoter or miR-29b regulatory
regions were incubated with recombinant pro-
teins NFkBp50 and p65, and supplemented with
recombinant proteins Sp1 (lanes 3 and 8), HDAC1
(lanes 4 or 9), or HDAC3 (lanes 5 or 10). Additional
complexes seen only with miR-29b probe were
indicated with arrow. In right panel, ChIP assays
showed that Sp1/NFkB/HDACs were enriched on
miR-29b enhancer.
(B) ChIP assays showed that HDAC1 and HDAC3
had higher DNA binding affinity on miR-29b than
KIT regulatory element (mean ± SEM).
(C) miR-29b transcription inversely related to the
level of HDAC1 in Kasumi-1 cells transfected
with HDAC1 siRNA or overexpression construct
(mean ± SEM).
(D) HDAC inhibitor (HDAC42) enhanced miR-29b
transcription determined by qRT-PCR (mean ±
SEM).
(E) HDAC inhibition by HDAC42 concurrently
reduced Sp1 and KIT RNA (left panel) (mean ±
SEM) or protein (middle panel) expression in
Kasumi-1 cells. Conversely, HDAC1 overexpres-
sion increased Sp1 and KIT level (right panel).
(F) HDAC inhibition by HDAC42 abrogated Sp1/
NFkB/HDAC repressor complex. In left panel,
ChIP assays demonstrated that the disruption
of Sp1/NFkB/HDAC complex and the accumula-
tion of acetylated histone H3 (ac-HD3) and H4
(ac-HD4) on miR-29b regulatory region (mean ±
SEM). In right panel, coimmunoprecipitation
showed that HDAC42 disrupted Sp1/HDAC1 inter-
action. Data are representative of three indepen-
dent experiments. (See also Figure S5).
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MicroRNA Network Regulating KIT Expression in AMLMYC and decrease inmiR-29b in THP-1 cells, which, when unsti-
mulated, express relatively low KIT levels and higher miR-29b
levels (Figure 7A). Similarly, overexpression of KITmut or KITwt in
THP-1 cells resulted inMYC upregulation andmiR-29b downre-
gulation (Figure 7B). Finally, ectopic expression ofMYC resulted
in downregulation ofmiR-29b (Figure 7C, left panel) and upregu-
lation of the miR-29b target Sp1 (Figure 7C, middle panel),
thereby resulting in higher levels of KIT expression in Kasumi-1
and MV4-11 cells (Figure 7C, right panel).
For further determining the biologic role of KIT protein abun-
dance, KIT expression was knocked out by siRNA in Kasumi-1
cells. We observed miR-29b upregulation and Sp1 downregula-
tion (Figure 7D), decrease of the Sp1/NFkB complex binding to340 Cancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc.rthe KIT promoter as demonstrated by
EMSA assays (Figure 7E) and significant
antileukemic activity in Kasumi-1 cells
(Figures S6A–S6E). Finally, we demon-
strated that bortezomib treatment alsoled to a decrease in MYC protein expression (Figure 7F). Alto-
gether, these results support that MYC-induced miR-29b
downregulation, occurring upon activation of the KIT protein in
leukemia cells, leads to the KIT gene overexpression through
the Sp1/NFkB/HDAC/miR-29b network. A summary diagram
that outlines the above regulatory network is described in
Figure 7G.
Treatment with Bortezomib Suppresses In Vivo
KIT-Driven Leukemogenesis
Having demonstrated the relevance of the Sp1/NFkB/miR-
29b feedback loop on KIT regulation, we next tested whethe
this loop represented a potentially viable therapeutic target to
Cancer Cell
MicroRNA Network Regulating KIT Expression in AMLovercome KIT-driven leukemia in vivo. We cloned D816V KITmut
or KITwt into pBABE-puro retroviral vector and stably expressed
these constructs in the FDC-P1 cell line, a murine nontumori-
genic diploid cell line derived from myeloid precursors. In
in vitro studies, we observed that overexpression of either KITmut
or KITwt promoted cell proliferation determined by clonogenic
assay, albeit more pronounced effects were attained with KITmut
(Figure S7A). In order to investigate the leukemic role of KIT
protein in vivo, FDC-P1/KITmut cells (5 3 106/mouse) were then
engrafted into NOD/SCID mice, which developed significant
splenomegaly (Figure 8A) and died from a leukemia-like illness
within 4 weeks. In contrast, no evidence of disease was
observed in empty-vector transfected FDC-P1 parental cells.
Western blot confirmed KIT expression in the enlarged spleen
of FDC-P1/KITmut engrafted mice (Figure 8A).
Additional in vivo experiments were performed to demonstrate
the potential therapeutic relevance of KIT downregulation. We
selected bortezomib among the different compounds that we
showed to interfere with the Sp1/NFkB/miR-29b regulatory
loop, as this compound targets Sp1/NFkB complex, upregulates
miR-29b and is an FDA-approved anticancer drug. Sp1/NFkB
binding sites were found by computational methods (http://
www.cbrc.jp/research/db/TFSEARCH.html) in the promoter
region of the pBABE vector carrying KITmut and used to transfect
FDC-P1 cells (not shown). In vitro, bortezomib treatment
inhibited proliferation (Figure 8B, left panel) and decreased
clonogenic activity (Figure 8B, right panel) of FDC-P1/KITmut
cells. These effects were associated with Sp1 and KIT protein
downregulation, KIT protein hypophosphorylation, andmiR-29b
upregulation (Figure 8C). In contrast, forced Sp1 or NFkB(p65)
expression enhanced mutated KIT (Figure 8D, left panel) and
ectopic miR-29b expression inhibited colony-forming ability in
FDC-P1/KITmut cells (Figure 8D, right panel). These findings
therefore supported the relevance of the Sp1/NFkB/miR-29b
regulatory complex to KIT expression and the pharmacologic
activity of bortezomib in FDC-P1/KITmut cells, thereby validating
FDC-P1/KITmut engrafted mice as a suitable in vivo model
for KITmut-driven leukemia. Similar results were also achieved
in FDC-P1/KITwt cells exposed to bortezomib (Figures S7B
and S7C).
NOD/SCID mice engrafted with FDC-P1/KITmut cells were
then treatedwith one dose bortezomib (1mg/kg/dose) and sacri-
ficed 48 hr later. We observed that bortezomib abrogated KIT
mRNA transcription and protein expression and increased
miR-29b expression in vivo (Figure 8E). The role of miR-29b
upregulation as a potential key step in the therapeutic response
of KIT-driven leukemia to bortezomib was further supported by
a decreased engraftment efficiency of FDC-P1/KITmut cells
transfected with synthetic miR-29b. The size and weight of
murine FDC-P1/KITmut tumors from cells pretreated with miR-
29b was significantly lower than those of cells pretreated with
vehicle alone or scrambled miRNA when measured at day 21
after engraftment (Figure 8F and Figure S7D).
Next, FDC-P1/KITmut-engrafted mice were treated with
1 mg/kg bortezomib once or twice weekly for 3 weeks, starting
at day 21 after engraftment (n = 5mice/group), and then followed
longitudinally. Animals treated with bortezomib demonstrated
significantly longer periods of survivals than vehicle-treated
controls (Figure 8G). Vehicle-treated FDC-P1/KITmut engraftedmice exhibited massive splenomegaly, whereas spleen size
and weight of the bortezomib-treated animals were similar to
those of age-matched controls (Figure 8H). Cytospins of bone
marrow cells and histopathology of spleen and liver sections
from FDC-P1/KITmut-engrafted mice treated with vehicle
showed extensive infiltration of blast cells. In contrast, cytospins
of bonemarrow cells and histopathology of spleen and liver from
the bortezomib-treated leukemic mice were similar to that of the
age-matched control groups (Figure 8I).
To validate these in vivo data in a model where KIT expression
is controlled via an endogenous promoter, we next established
murine xenografts with the human mastocytosis HMC-1 cell
line carryingKITmut. These cells were sensitive in vitro to bortezo-
mib treatment which induced miR-29b upregulation, and Sp1
and KIT downregulation (Figures S7E and S7F). NOD/SCID mice
engrafted with 1 3 107 HMC-1 cells subcutaneously received
intratumor administration of 1 mg/kg bortezomib twice a week
for 2 weeks starting from when the tumor size approached
20 mm3. Significant decrease in tumor size was observed in bor-
tezomib-treated mice when compared with vehicle-treated
controls (Figure 8J). Similarly, bortezomib was therapeutically
advantageous in mice engrafted with ME-1 cells overexpressing
KITwt (Figure S7G). Collectively, these results indicate that KIT
overexpression significantly contributes to malignant cell prolif-
eration, and targeting KIT abundance through the miRNA-
protein network represents a promising therapeutic approach
to overcome KIT-driven leukemia.
DISCUSSION
Previous studies revealed that certain human cancers including
AML are characterized by aberrant KIT tyrosine kinase activity
(Beadling et al., 2008; Went et al., 2004). To date, much effort
has been focused on targeting aberrantly activated KIT mutants
using TK inhibitors. Although treatment with these compounds
can induce clinical responses in both solid tumors and hemato-
logic malignancies harboring KIT mutations (Heinrich et al.,
2008), this strategy is complicated by the needs for adjustment
of therapy based on individual KIT genotypes and early onset
of treatment resistance due to acquired secondary mutations
or/and KIT overexpression. Here we show that aberrantly acti-
vated KIT protein itself may drive upregulation of the KIT
gene, and high KIT expression is an important contributor to
malignant cell proliferation and aggressive disease. Our findings
therefore support the rationale for therapeutic targeting of KIT
abundance to overcome aberrant KIT activity and induce signif-
icant antileukemic effects. The current study was designed to
investigate mechanisms that regulate KIT expression, so that
treatment strategies attacking directly KIT gene deregulators in
leukemia can be developed to circumvent the drawbacks
encountered with TK inhibitor therapy. Our investigation indeed
led to the identification of a Sp1/NFkB/HDAC/miR-29b network
that deregulates KIT gene transcription, that impacts leukemo-
genesis, and that is targetable pharmacologically.
Previous investigations reported that miR-221/222 directly
target KIT expression (Felli et al., 2005). Here, we provide the first
evidence of an indirect but pivotal role ofmiR-29b in modulating
KIT expression in KITmut leukemia. By using computational anal-
yses we found lack ofmiR-29b binding sites in KITmRNA 30UTR.Cancer Cell 17, 333–347, April 13, 2010 ª2010 Elsevier Inc. 341
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MicroRNA Network Regulating KIT Expression in AMLHowever, treatment with ectopic miR-29b or compounds that
led to increase in endogenous miR-29b resulted in KIT downre-
gulation. We showed that this was due to an indirect effect on
KIT expression mediated by a miR-29b/Sp1 mutual feedback
loop. Sp1, a transactivator of the KIT gene, binds to the miR-
29b regulatory elements and represses miR-29b expression,
whereasmiR-29b blocks Sp1 translation and in turn upregulates
its own transcription. NFkB, a transcription factor that is in
part modulated by the 26S proteasome system and is constitu-
tively activated in AML, physically interacts with Sp1 to regulate
miR-29b and KIT expression. HDACs confer transcription
repressing activity to the Sp1/NFkB complex binding the miR-
29b regulatory elements in leukemia cells, but do not participate
in the Sp1/NFkB complex that binds and transactivates the
KIT promoter. Thus, when miR-29b is aberrantly suppressed
by a Sp1/NFkB/HDAC complex in KITmut leukemia, KITmut
becomes upregulated, thereby contributing to malignant prolif-
eration. But what is the primary event deregulating this miRNA-
protein network? We showed that gain-of-function mutations
or aberrant ligand-dependent activation of the KIT protein in
leukemia cells lead to constitutive MYC upregulation, which is
likely to produce the initial step for decreasing miR-29b below
a threshold that results in Sp1 increase, aberrantly high levels
of Sp1/NFkB/HDAC activity, and ultimately KIT upregulation.
The latter perpetuates autoregulatory loops that minimize miR-
29b expression and maximize KIT expression and activation in
leukemia cells.
Pharmacologic intervention with synthetic miR-29b oligonu-
cleotides or compounds that inhibit proteasome (bortezomib),
NFkB (bay11-7082), Sp1 (mithramycin A), andHDACs (HDAC42),
targets the Sp1/NFkB/HDAC complex in leukemia cells, and
sequentially results in endogenous miR-29b upregulation, Sp1
downregulation, disruption of the Sp1/NFkB complexes, and
inhibition of theKIT gene. The net results areKIT downregulation,
inhibition of aberrant TK activity, and arrest of leukemia growth.
The pivotal role of miR-29b in this miRNA/protein network is
supported by upregulation or downregulation of KIT expression
in response to repression of endogenous miR-29b or forced
expression of ectopic miR-29b, respectively. This was further
confirmed by showing that ectopicmiR-29b expression inhibited
the colony-forming ability and in vivo growth of KIT-driven
leukemia cells (FDC-P1/KITmut cells).
Sp1 and NFkB are ubiquitous transcription factors and are
overexpressed in human malignancies. We and others demon-
strated that Sp1 physically interacts with NFkB to enhance target
gene transactivation (Hirano et al., 1998; Liu et al., 2008). Here,
we showed that, like miR-29b, these two factors are located atFigure 7. Role of Activated KIT in KIT Gene Transcription
(A) Treatment with KIT ligand (stem cell factor) induced KIT and MYC upregulatio
(B) Overexpression of KITmut or KITwt increased MYC expression and decreased
(C) MYC overexpression increased KIT and Sp1 transcription and decreased miR
(D) KIT knockout by siRNA enhanced miR-29b expression leading to Sp1 downr
(E) EMSA demonstrated that siRNA-induced KIT knockout decreased Sp1/NFkB b
protein complexes was demonstrated by the abolishment or reduction of comple
sition of the gel.
(F) MYC protein expression is suppressed in Kasumi-1 cells treated with bortezo
(G) Summary diagram describes the Sp1/NFkB/HDAC/miR-29b network that regu
tions within the network that may result in the inhibition of KIT expression thereby i
also Figure S6).a central position within a regulatory network controlling KIT
expression. The proteasome inhibitor bortezomib, which effec-
tively interferes with the activity of Sp1/NFkB complex at
concentrations (i.e., 60 nM) that are achievable in patients
treated at the recommended dose of the drug (Quinn et al.,
2009), was then chosen to test the therapeutic relevance of tar-
geting KIT expression in KITmut leukemia. The intended in vivo
target for this compound was the Sp1/NFkB/HDAC/miR-29b
network. Our data indeed indicated that bortezomib disrupts
both Sp1/NFkB and Sp1/NFkB/HDAC complexes, thereby
resulting inmiR-29b upregulation, Sp1 downregulation, and inhi-
bition of the KIT gene transactivation. These events ultimately
result in strong antileukemic activity and improved survival in
NOD/SCID mice that were engrafted with FDC-P1/KITmut cells.
Similar results were also attained in mice xenografted with
malignant cells overexpressing KIT under the control of an
endogenous promoter. Thus, bortezomib appears to be a poten-
tially effective treatment for KIT-driven leukemia, despite that
it is not predicted by computer-modeling to bind to the same
KIT enzymatic pocket where interaction with PKC412, imatinib,
or other tyrosine kinase inhibitor small molecules occurs (not
shown).
In conclusion, our investigation has identified a critical regula-
tory Sp1/NFkB/HDAC/miR-29b network that modulates KIT
expression. We show that aberrant activation of KIT results in
MYC-dependent miR-29b downregulation and an increase in
Sp1 expression. The latter interacts with NFkB and HDACs to
further inhibit miR-29b expression, and with NFkB alone to
transactivate KIT. Because of the central role of Sp1/NFkB
complex in mechanisms of KIT dysregulation, proteasome
inhibition appears particularly advantageous to target therapeu-
tically this network. Similar pharmacologic effects can be
also achieved through inhibition of NFkB (by bay11-7082),
Sp1 (by mithramycin A), HDAC1/3 (by HDAC42), or addition of
miR-29b. Notably, our previous reports show that miR-29b
controls the expression of DNA methyltransferases and restores
epigenetically silenced gene expression and cell differentiation
patterns in AML blasts displaying DNA hypermethylation (Liu
et al., 2008; Garzon et al., 2009). Therefore, therapeutic targeting
of the Sp1/NFkB/HDAC/miR-29b network may lead to control
not only of KIT, but also of other aberrantly expressed onco-
genes (i.e., DNMTs) that, though not directly involved in regula-
tion of KIT expression, may play an equally relevant role in leuke-
mogenesis. Importantly, many of the pharmacologic agents that
we have used to target KIT expression are already in the clinic.
Thus, we believe that an attractive aspect of our study points
to the possibility of rapidly translating our findings into clinicaln and miR-29b downregulation in THP-1 cells harboring KITwt (mean ± SEM).
miR-29b downregulation in THP-1 cells (mean ± SEM).
-29b expression in KITmut Kasumi-1 and KITwt MV4-11 cells (mean ± SEM).
egulation in Kasumi-1 cells transfected with KIT siRNA (mean ± SEM).
inding affinity on its own promoter. The presence of NFkB and Sp1 in the DNA-
xes with antibody supershift assay. Note, the inserted lines indicate the repo-
mib for 24 hr.
lates KIT expression. Indicated are also sites of potential therapeutic interven-
ts activity. Data (A-F) are representative of three independent experiments. (See
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Figure 8. In Vivo Activity of Bortezomib on KITmut-Driven Leukemia
(A) Mice engrafted with FDC-P1/KITmut cells developed leukemia-like disease with enlarged spleens. Shown on the left are spleens frommice injected with FDC-
P1/KITmut cells. As shown in the middle, immunoblotting indicated the presence of human KIT expression in the spleen from the mice engrafted with FDC-P1/
KITmut cells, but not in FDC-P1/vector only cells. Shown on the right is a graph of spleen weight (mean ± SD).
(B) Bortezomib inhibited proliferation (left panel) and colonogenic activity (right panel) in FDC-P1/KITmut cells (mean ± SEM).
(C) Bortezomib treatment decreased Sp1 and KIT protein (left panel) and RNA (middle panel) expression and increasedmiR-29b level (right panel) (mean ± SEM)
in FDC-P1/KITmut cells.
(D) Forced Sp1 and NFkB expression in FDC-P1/KITmut cells increased KIT level (left panel) and ectopicmiR-29b expression inhibited the colonogenic activity in
FDC-P1/KITmut cells (right panel) (mean ± SD).
(E) KIT protein expression (left panel) was decreased andmiR-29b transcription was increased (right panel) (mean ± SEM) in FDC-P1/KITmut cell engrafted mice
48 hr following in vivo treatment with bortezomib.
(F) Ectopic miR-29b expression significantly inhibits tumor growth in mice engrafted with FDC-P1/KITmut cells transfected with synthetic miR-29b.
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Cancer Cell
MicroRNA Network Regulating KIT Expression in AMLtrials targeting molecular subsets of AML in which the Sp1/
NFkB/miR-29b network appears to play a central role for onco-
gene expression.
EXPERIMENTAL PROCEDURES
Plasmids and Cell Lines
Construction of the human Sp1 in EBV/retroviral hybrid vector and cell culture
(Kasumi-1, K562, MV4-11, THP-1) were done as previously reported (Liu et al.,
2008). KIT expression plasmids (KITmut and KITwt) were constructed by insert-
ing the KIT gene sequence into pBABE-puro retroviral vector. pCMV-p65
expressing NFkB (p65) and pcDNA3-Flag-HDAC1 expressing HDAC1 (Taun-
ton et al., 1996) were also used. Retroviral infection to establish FDC-P1 cell
line stably expressing KITmut or KITwt was performed as previously reported
(Neviani et al., 2007).
Cells were treated with the following reagents (concentrations, times, and
schedules indicated in Results): bortezomib (Millennium Pharmaceuticals
Inc., Cambridge, MA), MS275, mithramycin A, decitabine, and PKC412
(Sigma-Aldrich, St Louis, MO), HDAC-OSU 42 (HDAC42) (OSU, Columbus,
OH) (Sargeant et al., 2008), or bay11-7082 (Abcam Inc., Cambridge, MA).
Patient Samples
Mononuclear cells (MNC) from pretreatment BM samples with > 70% of blasts
from AML patients with t(8;21) were obtained from the OSU Leukemia Tissue
Bank. All patients signed the informed consent for the OSU 1997C0194
protocol to store and use their leukemia tissue for discovery studies. The
OSU 1997C0194 protocol was approved by the OSU Cancer Institutional
Review Board (IRB) Committee.
Gene Expression in AML Patients
KIT, Sp1, and miR-29b expression levels were measured in RNA samples of
BM MNC from CBF and CN AML patients enrolled on CALGB treatment
studies 8525, 9621, and 19808, using the Affymetrix U133 Plus 2.0 GeneChips
(KIT and Sp1) (Affymetrix, Santa Clara, CA) and OSU microRNA microarray
chip as previously reported (Radmacher et al., 2006; Marcucci et al., 2008).
For the gene expression microarrays, summary measures of the expression
levels were computed for each probe set using the robust multichip average
method, which incorporates quantile normalization of arrays (Irizarry et al.,
2003). For the microRNA expression microarrays, summary measures of
expression levels were computed for each probe using quantile normalization,
making an adjustment for array batch (Rao et al., 2008). Samples for analyses
were obtained from patients who were enrolled on CALGB clinical studies and
signed an informed consent for CALGB 20202 to store and use their leukemia
tissue for molecular characterization of AML. The CALGB 20202 protocol was
locally approved by the OSU Cancer IRB Committee.
Transient Transfection, Immunoprecipitation, and Western Blotting
On-targetplus Smart pool SiRNA for Sp1, NFkBp65, KIT, and HDAC1 were
purchased from Thermo Fisher Scientific (Waltham, MA). Precursor miR-29b
was from Applied Biosystems (Foster City, CA). Antago-miR-29b was from
Exiqon, Inc (Woburn, MA). SiRNA, miRNA oligos, or plasmid constructs were
introduced into leukemia cell lines by Nucleofector Kit (Lonza Walkerrsville
Inc, Walkersville, MD) according to the manufacturer’s instruction. The immu-
noprecipitation andwestern blots were preformed as previously described (Liu
et al., 2008). The antibodies used were: Sp1, total KIT, p-tyrosine, p-ERK (tyr
204) and b-actin (Santa Cruz Biotechnology, Santa Cruz, CA); phospho-KIT
(tyr719), phospho-p65 (Ser536), phospho-IKBa (Ser32), phospho-Stat3
(Tyr705), phospho-Stat1 (tyr701), phospho-Stat5 (ser694), phosphor-Akt, total(G) Bortezomib administered at the dose of 1 mg/kg once a week or twice we
compared with untreated FDC-P1/KITmut cell engrafted controls.
(H) Spleens from FDC-P1/KITmut cell engrafted mice untreated versus bortezom
(I) May-Grumwald/Giemsa staining of BM cells and H&E staining of sections from
mib-treated. FDC-P1/empty vector cell engrafted mice were also used as contro
(J) Tumor growth was inhibited in mice engrafted with HMC-1 cell after the admin
dent experiments. (See also Figure S7).Akt, total Erk, total Stat1, total Stat3, and total Stat5 (Cell Signaling Tech-
nology, Danvers, MA); ubiquitin (Millipore, Billerica, MA).
Electrophoretic Mobility-Shift Assays
EMSA with nuclear extracts and 32P-labeled probes were performed as
described (Hong et al., 2003; Liu et al., 2008). The primers for KIT and miR-
29b promoter are listed in Supplemental Information. Recombinant proteins,
NFkB(p50), and Sp1 (Promega, Madison, WI), NFkB(p65), and HDAC1 and
HDAC3 (Caymanchem, Ann Arbor, MI) were purchased.
Real-Time RT-PCR
For normalized expression of KIT, MYC and Sp1, qRT-PCR was performed as
described elsewhere (Marcucci et al., 2005). For miRNA expression, qRT-PCR
was carried out by TaqManMicroRNAAssays (Applied Biosystems) according
to the manufacturer’s protocol and normalized by U44/48 (for human) or
Sno202 (for mouse) levels. Expression of the target genes were measured
using the DCT approach.
Chromatin Immunoprecipitation
ChIP assays were performed using the EZ ChIP Assay Kit (Millipore) according
to the manufacturer’s standard protocol. DNA was quantified using qRT-PCR
with SYBR green incorporation (Applied Biosystems). The antibodies used
were: anti-acetyl-histone H4, acetyl-histone H3, HDAC1, HDAC3, Sp1, and
NFkB(p65) (Millipore). The primers specific for KIT gene promoter or miR-
29b enhancer are listed in Supplemental Information.
Leukemogenesis in NOD/SCID Mice
Four to six-week-old NOD/SCID (The Jackson Laboratory, Bar Harbor, ME)
were intravenously injected through the tail vein with 5 3 106 cells of FDC-
P1 cells harboring D816V KITmut. After engraftment, cell-injected mice (n = 5)
were intravenously treated with 1 mg/kg bortezomib via tail-vein in 0.2 ml
saline solution once or twice a week. Longitudinal follow-up to assess survival
was conducted and the trial was terminated 8.5 weeks after injection. Mice in-
jected with FDC-P1/KITmut cells (n = 5) and injected with saline solution only
served as controls. The effect of bortezomib on targets (KIT and miR-29b)
was tested in vivo in FDC-P1/KITmut-engrafted mice (n = 4) treated with
1 mg/kg bortezomib and assessed for KIT and miR-29b expression 48 hr
following drug administration. Following euthanasia, isolated spleens were
grounded, and the red blood cells were lysed to attain single MNCs utilized
for immunoblotting and qRT-PCR assays. For pathological examination, tissue
sections from liver and spleen were fixed on formalin, embedded in paraffin
blocks, and H&E stained. The effect of a synthetic miR-29b engraftment
ability of FDC-P1/KITmut was tested by engrafting FDC-P1/KITmut cells trans-
fected withmiR-29b, scrambled miRNA, or vehicle. The transfection efficiency
of the miRNA compounds was approximately 50%–60% as evaluated by
concurrent transfection of a plasmid expressing GFP.
Finally, NOD/SCID mice were also injected with 1 3 107 HMC-1 or ME-1
cells subcutaneously. When tumor size approached approximately 20 mm3,
the animals received 1 mg/kg bortezomib or vehicle alone twice a week (intra-
venous bolus) for 2 weeks. The experiments were terminated in two weeks
after drug administration. All animal studies were performed in accordance
with OSU institutional guidelines for animal care and under approved protocols
(OSU 2007A0149 and 2008A0027) by the OSU Institutional Animal Care and
Use Committee.
Statistical Analysis
Statistical analyses relative tomicroarray gene andmicroRNA expression data
were performed by the CALGB Statistical Center.ekly increased survival duration in mice engrafted with FDC-P1/KITmut cells
ib-treated (mean ± SD).
spleen and liver of FDC-P1/KITmut cell engrafted mice untreated and bortezo-
l.
istration of bortezomib (mean ± SD). Data are representative of three indepen-
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